Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
aMoon Fund is a global venture capital fund based in Israel, founded in 2017 by Dr. Yair Schindel and Marius Nacht. The fund manages $1.1 billion in assets under management and focuses on healthcare and biotech sectors. It operates through its aMoon Velocity and aMoon Growth funds, along with an Edge Fund for IPO and public equity opportunities.
aMoon invests in early and late-stage healthcare companies, targeting disruptive technologies that are generating revenue or are in pivotal clinical trials. The fund participates in investment stages from pre-seed to growth equity, with a particular emphasis on companies that can address high unmet medical needs.
Notable portfolio companies include ACET (NASDAQ: ACET), AKYA (NASDAQ: AKYA), ADXS (NASDAQ: ADXS), OMDA (NASDAQ: OMDA), SEER (NASDAQ: SEER), SERA (NASDAQ: SERA), SOPH (NASDAQ: SOPH), and VIRX (NASDAQ: VIRX), which was acquired by Nanox (NASDAQ: NNOX).
Email info@amoon.fund with your deck to pitch aMoon Fund.
Yes, aMoon Fund often leads investment rounds, particularly in early-stage companies that align with their healthcare focus.
aMoon is open to follow-on investments, especially for companies that demonstrate significant growth potential and are addressing unmet medical needs.
The fund currently manages $1.1 billion in assets under management, making it one of the largest HealthTech venture capital funds in Israel.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.